Notogen is an early-stage biotechnology company developing a biological therapy for degenerative disc disease (DDD; chronic back/neck pain due to degenerating spinal discs). Notogen has compelling large animal data and is currently seeking investors/partners to support a Phase 1/2a clinical trial planned for 2021. DDD is a huge market opportunity with high unmet needs and does not have disease modifying treatments.

Notogen Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total